Zejula is a PARP inhibitor drug which is used to treat ovarian cancer in the UK.
Zejula was developed by the pharmaceutical company GlaxoSmithKline.
Zejula is currently being studied in a phase 3 clinical trial. This trial is investigating how well Zejula works in advanced prostate cancer which has spread outside the prostate when it is used along with a hormone therapy drug (abiraterone) and a steroid (prednisone). However, this trial is not due to end until early 2025.
To find out more about the typical timescales involved in developing new drugs and more information about clinical trials please click here.
To find out more about Zejula please click here.
If you are interested in hearing updates about Zejula’s development journey please fill out your details below and we will be sure to update you when we have news. This information will not be used for any purpose other than providing you updates on Zejula and will not be shared outside our organisation.